CHD1L and plasma cell myeloma: Bortezomib decreased the protein levels of CHD1L, but cell adhesion increased the expression levels of CHD1L, overexpression of CHD1L contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells [6].